ANTIVIRAL DRUG KINETICS IN VITREOUS USING MICRODIALYSIS

$209,218R01FY2002EYNIH

University Of Missouri Kansas City, Kansas City MO

Investigators

Linked publications & trials

Paper 29339145 Paper 28471177 Paper 28087407 Paper 27967247 Paper 27798766 Paper 27573097 Paper 27010987 Paper 26964498 Paper 26828415 Paper 26706439 Paper 26561725 Paper 25940041 Paper 25888804 Paper 25844889 Paper 25590022 Paper 25575654 Paper 25491667 Paper 25425389 Paper 25414810 Paper 25400717 Paper 25364778 Paper 25319053 Paper 25315374 Paper 25251334 Paper 25106908 Paper 25014399 Paper 24980081 Paper 24943988 Paper 24895075 Paper 24888969 Paper 24697179 Paper 24592957 Paper 24504495 Paper 24202050 Paper 24192229 Paper 24157270 Paper 24102496 Paper 23861613 Paper 23861607 Paper 23827654 Paper 23701276 Paper 23626400 Paper 23464520 Paper 23428883 Paper 23331181 Paper 23323774 Paper 23215539 Paper 23137392 Paper 23122404 Paper 23116562 Paper 22927035 Paper 22803583 Paper 22676443 Paper 22530907 Paper 22499243 Paper 22493994 Paper 22420308 Paper 22044356 Paper 21978133 Paper 21858246 Paper 21830912 Paper 21501073 Paper 21500985 Paper 21278830 Paper 21171952 Paper 20939702 Paper 20874666 Paper 20565313 Paper 20437123 Paper 20172680 Paper 20148659 Paper 20028257 Paper 19232011 Paper 19172464 Paper 19075883 Paper 18958406 Paper 18758924 Paper 18638532 Paper 18573320 Paper 18472234 Paper 18207340 Paper 18040809 Paper 17803430 Paper 17686592 Paper 17683251 Paper 17593010 Paper 17363204 Paper 17250788 Paper 17238815 Paper 17156953 Paper 17097248 Paper 17083930 Paper 17050273 Paper 17038304 Paper 16910863 Paper 16889437 Paper 16769607 Paper 16722797 Paper 16720085 Paper 16459033

Abstract

DESCRIPTION: (Adapted from Applicant's Abstract) In this competing renewal application, the Principal Investigator proposes to study the vitreal pharmacokinetics of ganciclovir, foscarnet, and cidofovir, three antiviral agents used to treat cytomegalovirus. A relatively new procedure, microdialysis, will be used which has the advantage of measuring drug levels in a continuous manner. By using this approach and from the experiments that are planned in pigmented rabbit eyes, it will be possible to more thoroughly determine each drug's ocular kinetics than from using previously methods in which each time interval represented a different group of animals. In addition, the investigator proposes to determine physico-chemical and biological determinants that help to explain ganciclovir's distribution and elimination profile. From this information, the investigator plans to develop approximately eighteen prodrugs that in theory could optimize antiviral therapy by prolonging drug levels in the vitreous.

View original record on NIH RePORTER →